Stock info Morphosys | Filter  Basic-Info

Morphosys

The past year was a good year for Morphosys investors

The period between December 2015 and December 2016 was a loss-making period for the investors in Morphosys . The stock lost around 16 percent. Over the period 2011-2016 the stock rose a massive 175,38 percent. Morphosys 's revenues between 2011 and 2015 were very fluctuating and moved between 51,92 million euros and 106,22 million euros. Morphosys 's net results between 2011 and 2015 were far from constant and moved between 8,22 million euros and 14,9 million euros.

Morphosys primarily operates in the biotech sector. The past 10 years the (international) industry gained at around 59 percent. Over the past 5 years the sector is 70 percent higher.

Over the past 5 years the German company paid out dividends.

At the end of 2015 the company had around 315 people employed.

Morphosys financed with lots of debt

Last year the balance sheet of the German company was worth 400,08 million euros. The total debt was around 37,34 million euros. This is 9,33 percent of the total balance sheet. At the end of 2016 the German company was traded with a price/earnings-ratio of around 106. So investors paid 106 times the company's 2015's EPS. Based on the classical stock valuation theories the German stock can be seen as a growth stock.

The biotech company's market capitalization (the number of shares outstanding times the market value) equaled around 1,48 billion euros. At the end of 2015 the German company had around 26,02 million stocks listed.

All Morphosys 's financial reports are located here. More information about Morphosys can be found it's website. .